[Notice of expert for modality and prescriptions limits of local estrogenotherapy for urinairy inconfinence in women]. / Avis d'experts sur les modalités et limites de prescription des estrogènes locaux dans l'incontinence urinaire chez la femme.

OBJECTIVE: To develop a consensus of experts on the use of local estrogens in female urinary incontinence. MATERIAL AND METHOD: Following a formalized consensus method (DELPHI), a questionnaire was produced and sent to a first round and then to a second round of experts. The questionnaire consisted of proposals for recommendations for the use of local estrogens in the context of female urinary incontinence. The Survey Monkey® survey software allowed the questionnaire to be distributed and the answers obtained to be analyzed. RESULTS: Eight experts responded to the first round questionnaire. Seven formulations were deleted, 3 amended and 4 added to the first round questionnaire following expert advice. Twenty-six experts replied to the second round questionnaire, 24 of which were complete. Ten of the 21 proposals were approved at more than 80%, including five with strong agreement regarding the recognized benefit of local estrogens in urinary incontinence due to overactive bladder, the absence of data from the literature to demonstrate over-risk of hormone-dependent cancer under local estrogens and the need for follow-up of patients under this treatment. Six proposals were not the subject of a consensus and concerned the prescription modalities (maximum duration, effective minimum dose, prescription before surgery for incontinence). CONCLUSION: Although local estrogens did not have regulatory approval in urinary incontinence, more than 80% of these experts recognized their benefit in the management of urinary incontinence in women with vulvo-vaginal atrophy, particularly in the case of urinary urge incontinence. LEVEL OF PROOF: 4.

[Hospitalization rate in relation to severe complications of transrectal prostate biopsy: About 2715 patients biopsied]. / Taux d'hospitalisations en rapport avec des complications sévères des biopsies de prostate transrectales : à propos de 2715 patients biopsiés.

MAIN OBJECTIVE: To identify hospitalizations directly related to a complication occurring within 30 days following a transrectal prostate biopsy (PBP). SECONDARY OBJECTIVES: Overall hospitalization rates, mortality rates, potential predisposing factors for complications. PATIENTS AND METHODS: Single-center study including all patients who underwent PBP between January 2005 and January 2012. Any hospitalization occurring within 30 days of the PBP for urgent motive was considered potentially attributable to biopsy. We identified the reason for hospitalization with direct complications (urinary infection or fever, rectal bleeding, bladder caillotage, retention) and indirect (underlying comorbidities decompensation) of the biopsy. The contributing factors were anticoagulant or antiplatelet treatment well as waning immunity factors (corticosteroid therapy, HIV, chemotherapy or immunodulateur). RESULTS: Among 2715 men who underwent PBP, there were 120 (4.4%) hospitalizations including 28 (1.03%) caused by the biopsy. Twenty-five (0.92%) were related to a direct complication of biopsy: 14 (56%) for urinary tract infection or fever including 1 hospitalization in intensive care, 5 (20%) for rectal bleeding which required several transfusions 1, 10 (40%) urinary retention and 3 (0.11%) for an indirect complication (2 coronary syndromes and 1 respiratory failure). Several direct complications were associated in 3 cases. Only two hospitalizations associated with rectal bleeding were taking an antiplatelet or anticoagulant. There was no association between hospitalization for urinary tract infections and a decreased immune status. The first death observed in our study occurred at D31 of pulmonary embolism (advanced metastatic patient with bladder cancer). Twenty (60.6%) patients urgently hospitalized did not have prostate cancer. CONCLUSIONS: Within this large sample of patients the overall rate of hospitalization due to the realization of a PBP was 1%. It has not been found predictive of complications leading to hospitalization. LEVEL OF EVIDENCE: 4.

[Patient information before bladder wall injection of botulinum toxin A (Botox®): Which essential items? Results of Delphi consensus from GENULF experts]. / Information patient avant injection de toxine botulique intradétrusorienne (Botox®) : quels sont les items indispensables ? Résultats d'un consensus Delphi d'experts du Groupe d'étude de neuro-urologie de langue française (GENULF).

INTRODUCTION: Preoperative information before bladder wall injection of botulinum toxin A (Botox®) holds several essential facts to understand and retain by the patients. The aim of this study was a review of essential preoperative information items according to GENULF medical experts. METHOD: It was a prospective review from December 2015 to April 2016. Three Delphi rounds had been done from the Survey Monkey® software. The initial questionnaire was composed of items from the patient information sheet edited by the GENULF. Each item had been rated by the medical expert on a numeric scale of importance for patient information. The last round asked to experts to confirm items eventually selected. RESULTS: A list of 27 items regarded as essentials for patient information had been checked by experts after three Delphi rounds, confirmed by 15/19 experts (75%). Best rated items were "learning self-catheterisation is essential" (mean interest 8,5/9 ; number of rate 8 or 9: 15), "kidney are protected over the long term" (mean interest 8,3/9 ; number of rate 8 or 9: 15), "efficiency is 6 to 9 months long" (mean interest 8,2/9 ; number of rate 8 or 9: 14). Discrepancies were mostly on lack of distinction between neurologic and non-neurologic patients. CONCLUSION: We identified accurate items considered as essential for preoperative information to patients before bladder wall injection of botulinum toxin A (Botox®) by a Delphi method recommended by HAS. LEVEL OF EVIDENCE: 4.

[Ejaculation capacity in spinal cord injured patients carrying an endo-urethral stent for incontinentation: Descriptive study]. / Capacité éjaculatoire chez les sujets blessés médullaires porteurs d'une prothèse endo-urétrale d'incontinentation : étude descriptive.

OBJECTIVES: To assess the impact of endo-urethral stent (EUP) of incontinentation in spinal cord injured (SCI) men on ejaculation capacity. FIRST CRITERIA: Presence of ejaculation after EUP. SECONDARY CRITERIA: Modification on ejaculation type, stimulation mode, possibility of sperm conservation in the same population. POPULATION AND METHODS: A descriptive monocentric study including SCI subjects which underwent placement or change of temporary (Mémokath™ or Allium™) or definitive (Mémotherm™) EUP between January 2004 and January 2014 with at least one ejaculatory test. Are identified for each patient: the presence of ejaculation, type of ejaculation, stimulation mode used, number of frozen specimen and results from semen analysis. RESULTS: Over 11 men with tetraplegia, complete for motricity, there were 8 (72%) for whom ejaculation was possible after laying EUP. Of these, 6 (55%) had an antegrade or antero-retrograde ejaculation. It was not possible to make a freezing straw in four of them due to infection of semen (2) or terato-oligo-astenospermia (1) or absence of reproductive project (1). CONCLUSION: In this small sample, it was found that over 70% ejaculation have been preserved after laying EUP and more than 50% with antegrade or antero-retrograde ejaculation. A larger study would identify how EUP may alter the ejaculatory capacity or quality of the ejaculate. LEVEL OF EVIDENCE: 4.